

Tomoki Naoe

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10405504/tomoki-naoe-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

16,159
citations

58
h-index

126
g-index

166
ext. papers

18,595
ext. citations

4.8
avg, IF

6
L-index

#	Paper	IF	Citations
160	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447	2.2	2764
159	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
158	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009 , 113, 1875-91	2.2	720
157	let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. <i>Biological and Pharmaceutical Bulletin</i> , 2006 , 29, 903-6	2.3	525
156	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. <i>Oncogene</i> , 2000 , 19, 624-31	9.2	451
155	High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2006 , 24, 460-6	2.2	354
154	Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. <i>Clinical Cancer Research</i> , 2007 , 13, 5124-32	12.9	347
153	Downregulation of microRNAs-143 and -145 in B-cell malignancies. <i>Cancer Science</i> , 2007 , 98, 1914-20	6.9	250
152	Decreased expression of microRNA-143 and -145 in human gastric cancers. <i>Oncology</i> , 2009 , 77, 12-21	3.6	244
151	Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. <i>Blood</i> , 2005 , 106, 2854-61	2.2	225
150	Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. <i>Oncogene</i> , 2002 , 21, 2555-63	9.2	220
149	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019 , 133, 1630-1643	2.2	219
148	Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. <i>Blood</i> , 2004 , 103, 1901-8	2.2	214
147	Presentation and management of intravascular large B-cell lymphoma. <i>Lancet Oncology, The</i> , 2009 , 10, 895-902	21.7	210
146	MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. <i>Oncology Reports</i> , 2006 , 16, 845-50	3.5	203
145	Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. <i>Molecular Therapy</i> , 2011 , 19, 395-9	11.7	194
144	Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3189-95	2.2	192

143	MicroRNA-143 and -145 in colon cancer. <i>DNA and Cell Biology</i> , 2007 , 26, 311-20	3.6	188
142	Integrin activation and matrix binding mediate cellular responses to mechanical stretch. <i>Journal of Biological Chemistry</i> , 2005 , 280, 16546-9	5.4	181
141	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. <i>Blood</i> , 2009 , 113, 4885-93	2.2	177
140	Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. <i>Blood</i> , 2011 , 117, 2358-65	2.2	174
139	Treatment With a New Synthetic Retinoid, Am80, of Acute Promyelocytic Leukemia Relapsed From Complete Remission Induced by All-trans Retinoic Acid. <i>Blood</i> , 1997 , 90, 967-973	2.2	162
138	Target antigen density governs the efficacy of anti-CD20-CD28-CD3 chimeric antigen receptor-modified effector CD8+ T cells. <i>Journal of Immunology</i> , 2015 , 194, 911-20	5.3	150
137	Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. <i>Blood</i> , 2004 , 104, 3507-12	2.2	150
136	Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. <i>Nature Genetics</i> , 2016 , 48, 569-74	36.3	141
135	Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. <i>Cancer</i> , 2005 , 103, 1652-8	6.4	141
134	Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 5620-8	3.4	136
133	A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. <i>Blood</i> , 2007 , 110, 59-66	2.2	134
132	Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1489-500	16.6	128
131	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As ₂ O ₃) in acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2013 , 97, 717-25	2.3	126
130	A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. <i>Blood</i> , 2011 , 117, 2366-72	2.2	125
129	Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. <i>British Journal of Haematology</i> , 1998 , 102, 1055-60	4.5	125
128	Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2014 , 1839, 1256-72	6	115
127	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. <i>Cancer Letters</i> , 2011 , 307, 211-20	9.9	114
126	Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. <i>European Journal of Haematology</i> , 2007 , 78, 213-9	3.8	100

125	Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. <i>American Journal of Pathology</i> , 2010 , 177, 547-54	5.8	98
124	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. <i>Blood</i> , 2009 , 114, 1607-17	2.2	98
123	Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. <i>British Journal of Haematology</i> , 1999 , 104, 659-64	4.5	92
122	Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. <i>Cancer</i> , 1993 , 71, 3888-95	6.4	87
121	Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. <i>Cancer Science</i> , 2016 , 107, 1422-1429	6.9	85
120	Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. <i>Blood</i> , 2011 , 118, 1600-9	2.2	84
119	Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. <i>Cancer Science</i> , 2010 , 101, 1480-6	6.9	83
118	Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. <i>Oncogene</i> , 2003 , 22, 9176-84	9.2	83
117	Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. <i>Life Sciences</i> , 2002 , 70, 2253-69	6.8	82
116	Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. <i>Japanese Journal of Cancer Research</i> , 2001 , 92, 638-44		77
115	BCR-ABL-transformed GMP as myeloid leukemic stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 17967-72	11.5	76
114	Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. <i>British Journal of Haematology</i> , 2000 , 108, 696-702	4.5	75
113	Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. <i>Leukemia Research</i> , 2009 , 33, 1530-8	2.7	74
112	Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. <i>Blood</i> , 2003 , 102, 2969-75	2.2	73
111	Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. <i>British Journal of Haematology</i> , 2008 , 143, 503-10	4.5	71
110	BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. <i>International Journal of Hematology</i> , 2005 , 82, 42-7	2.3	69
109	Tumor-suppressive microRNA-145 targets catenin $\beta 1$ to regulate Wnt/ β catenin signaling in human colon cancer cells. <i>Cancer Letters</i> , 2013 , 335, 332-42	9.9	68
108	Identification of non-coding RNAs embracing microRNA-143/145 cluster. <i>Molecular Cancer</i> , 2010 , 9, 136	42.1	67

107	Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. <i>Cancer Science</i> , 2015 , 106, 896-901	6.9	64
106	Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 1998 , 101, 521-8	4.5	64
105	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with mutations. <i>Blood</i> , 2018 , 131, 426-438	2.2	64
104	Nucleophosmin: a versatile molecule associated with hematological malignancies. <i>Cancer Science</i> , 2006 , 97, 963-9	6.9	59
103	FLT3 in human hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1541-7	1.9	59
102	Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. <i>Blood</i> , 2013 , 121, 3095-102	2.2	58
101	In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice. <i>Japanese Journal of Cancer Research</i> , 2001 , 92, 529-36		52
100	Gene mutations of acute myeloid leukemia in the genome era. <i>International Journal of Hematology</i> , 2013 , 97, 165-74	2.3	48
99	Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. <i>Molecular Therapy</i> , 2013 , 21, 1204-11	11.7	47
98	Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. <i>Haematologica</i> , 2008 , 93, 287-90	6.6	47
97	Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. <i>International Journal of Hematology</i> , 2006 , 83, 301-8	2.3	46
96	DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2013 , 1829, 1102-10	6	45
95	Acute myeloid leukemia in older adults. <i>International Journal of Hematology</i> , 2012 , 96, 186-93	2.3	45
94	Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 345, 1471-80	3.4	41
93	Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3729-35	2.2	40
92	Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. <i>International Journal of Hematology</i> , 2007 , 86, 49-57	2.3	39
91	Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. <i>American Journal of Pathology</i> , 2011 , 179, 1088-94	5.8	38
90	Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. <i>European Journal of Haematology</i> , 2009 , 83, 90-8	3.8	38

89	Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2008 , 140, 394-401	4.5	38
88	Phase I study of glasdegib (PF-04449913), an oral smoothed inhibitor, in Japanese patients with select hematologic malignancies. <i>Cancer Science</i> , 2017 , 108, 1628-1633	6.9	37
87	Antitumor effect of arsenic trioxide in murine xenograft model. <i>Cancer Science</i> , 2003 , 94, 1010-4	6.9	35
86	Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. <i>Japanese Journal of Cancer Research</i> , 2000 , 91, 1154-60		35
85	Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 390, 48-53	3.4	34
84	Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014 , 1843, 590-602	4.9	33
83	FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48 Suppl 1, S27-30	3.5	33
82	Novel heterozygous missense mutation in the platelet glycoprotein Ib beta gene associated with isolated giant platelet disorder. <i>American Journal of Hematology</i> , 2001 , 68, 249-55	7.1	32
81	Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: sequence non-specific recombination between the PML and RARA genes within identical short stretches. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 37-44	5	32
80	Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. <i>Japanese Journal of Cancer Research</i> , 1993 , 84, 379-87		32
79	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. <i>Leukemia Research</i> , 2018 , 66, 20-27	2.7	31
78	Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. <i>European Journal of Haematology</i> , 2005 , 74, 418-23	3.8	31
77	CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). <i>Leukemia Research</i> , 2013 , 37, 1021-6	2.7	30
76	Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1855-61	1.9	30
75	Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1747-53	1.9	30
74	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. <i>Cancer Science</i> , 2015 , 106, 1590-5	6.9	29
73	Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>International Journal of Hematology</i> , 2008 , 88, 149-153	2.3	29
72	A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. <i>Clinical Cancer Research</i> , 2007 , 13, 4575-82	12.9	29

71	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. <i>International Journal of Hematology</i> , 2012 , 96, 84-93	2.3	27
70	A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. <i>Transplantation</i> , 2007 , 83, 1242-8	1.8	27
69	Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. <i>International Journal of Hematology</i> , 2011 , 93, 66-73	2.3	26
68	BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. <i>European Journal of Haematology</i> , 2010 , 84, 229-38	3.8	26
67	B-cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells. <i>Immunology</i> , 2001 , 104, 410-7	7.8	25
66	Genes for thrombopoietin and c-mpl are not responsible for familial thrombocythaemia: a case study. <i>British Journal of Haematology</i> , 1998 , 100, 383-6	4.5	24
65	Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. <i>Leukemia Research</i> , 2000 , 24, 349-52	2.7	24
64	Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. <i>Oncotarget</i> , 2016 , 7, 47018-47032	3.3	24
63	Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2009 , 89, 3-13	2.3	23
62	Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. <i>International Journal of Hematology</i> , 2010 , 91, 276-83	2.3	23
61	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFβ-MYH11. <i>Blood Advances</i> , 2020 , 4, 66-75	7.8	22
60	Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. <i>Annals of Hematology</i> , 2018 , 97, 1535-1545	3	22
59	Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. <i>Cancer Science</i> , 2014 , 105, 97-104	6.9	22
58	SFK-STAT pathway: an alternative and important way to malignancies. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1086, 213-22	6.5	22
57	Efficacy and safety of human adipose tissue-derived mesenchymal stem cells for supporting hematopoiesis. <i>International Journal of Hematology</i> , 2012 , 96, 295-300	2.3	20
56	Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. <i>Cancer Genetics and Cytogenetics</i> , 1988 , 34, 77-88		20
55	Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. <i>PLoS ONE</i> , 2014 , 9, e92861	3.7	18
54	A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. <i>Cancer Genetics and Cytogenetics</i> , 1998 , 100, 21-4		18

53	Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2008 , 81, 454-60	3.8	18
52	CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. <i>Experimental Hematology</i> , 2012 , 40, 724-737.e2	3.1	17
51	Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. <i>International Journal of Hematology</i> , 2008 , 87, 144-151	2.3	17
50	Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway. <i>Leukemia and Lymphoma</i> , 2004 , 45, 987-95	1.9	17
49	Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. <i>Annals of Hematology</i> , 2019 , 98, 83-91	3	16
48	SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. <i>Cancer Science</i> , 2016 , 107, 1270-80	6.9	15
47	Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. <i>International Journal of Hematology</i> , 2012 , 95, 409-19	2.3	15
46	Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 320, 920-6	3.4	15
45	Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. <i>Leukemia</i> , 2019 , 33, 358-370	10.7	14
44	De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. <i>Cancer Science</i> , 2014 , 105, 35-43	6.9	14
43	Molecular heterogeneity of the PML gene rearrangement in acute promyelocytic leukemia: prevalence and clinical significance. <i>Japanese Journal of Cancer Research</i> , 1993 , 84, 257-64		14
42	Diversity of cellular molecules in human cells detected by monoclonal antibodies reactive with c-myc proteins produced in Escherichia coli. <i>Japanese Journal of Cancer Research</i> , 1989 , 80, 747-53		13
41	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2018 , 107, 201-210	2.3	12
40	Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. <i>Haematologica</i> , 2011 , 96, 174-6	6.6	12
39	FLT3/ITD regulates leukaemia cell adhesion through $\alpha 1$ integrin and Pyk2 signalling. <i>European Journal of Haematology</i> , 2011 , 86, 191-8	3.8	12
38	Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 169, 1-11		12
37	Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. <i>Cancer Science</i> , 2013 , 104, 1339-45	6.9	11
36	A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. <i>International Journal of Hematology</i> , 2011 , 93, 237-242	2.3	11

35	FLT3 mutations in acute myeloid leukemia. <i>Methods in Molecular Medicine</i> , 2006 , 125, 189-97		11
34	Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2008 , 48, 25-8	1.9	11
33	Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity. <i>Oncogene</i> , 2019 , 38, 2263-2274	9.2	11
32	Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. <i>Supportive Care in Cancer</i> , 2018 , 26, 4187-4198	3.9	10
31	Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 5472-7	2.9	10
30	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2016 , 97, 278-87	3.8	10
29	Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2018 , 103, e522-e526	6.6	10
28	The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. <i>Cancer</i> , 2013 , 119, 3326-33	6.4	9
27	Molecular cloning of the breakpoint of t(11;22) (q23;q11) chromosome translocation in an adult acute myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 1996 , 92, 687-91	4.5	9
26	Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 367-374	7.1	8
25	Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2011 , 35, 685-8	2.7	8
24	A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene. <i>Cancer Genetics and Cytogenetics</i> , 2003 , 144, 31-5		8
23	Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. <i>Annals of Hematology</i> , 2018 , 97, 73-81	3	8
22	Immunoaffinity purification and characterization of CACGTG sequence-binding proteins from cultured mammalian cells using an anti c-Myc monoclonal antibody recognizing the DNA-binding domain. <i>Journal of Biochemistry</i> , 1997 , 121, 550-9	3.1	7
21	Increased but highly dispersed levels of plasma glyocalicin in patients with disseminated intravascular coagulation. <i>European Journal of Haematology</i> , 1996 , 56, 173-7	3.8	6
20	Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography. <i>Scientific Reports</i> , 2018 , 8, 4008	4.9	5
19	Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. <i>International Journal of Hematology</i> , 2012 , 96, 485-91	2.3	5
18	Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2359-64	1.9	5

17	Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. <i>International Journal of Hematology</i> , 2006 , 84, 328-36	2.3	5
16	Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. <i>Cancer Science</i> , 2011 , 102, 1358-65	6.9	4
15	Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2020 , 99, 2787-2800	3	4
14	ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities. <i>FEBS Letters</i> , 2019 , 593, 2151-2161	3.8	3
13	Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. <i>International Journal of Hematology</i> , 2019 , 109, 418-425	2.3	3
12	Production of a truncated human c-myc protein which binds to DNA. <i>FEBS Letters</i> , 1988 , 240, 49-54	3.8	3
11	A Phase III Study of New Synthetic Retinoid Tamibarotene(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study. <i>Blood</i> , 2012 , 120, 410-410	2.2	3
10	Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature. <i>Cancers</i> , 2020 , 12,	6.6	2
9	Developing target therapy against oncogenic tyrosine kinase in myeloid malignancies. <i>Current Pharmaceutical Biotechnology</i> , 2006 , 7, 331-7	2.6	2
8	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. <i>Cancer Science</i> , 2020 , 111, 2472-2481	6.9	1
7	Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. <i>Leukemia Research</i> , 2018 , 65, 34-41	2.7	1
6	Tamibarotene for the treatment of acute promyelocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 961-969	1.1	1
5	Leukemia relapse reconsidered from the molecular aspect. <i>Leukemia and Lymphoma</i> , 2000 , 37, 527-34	1.9	1
4	<EditorsChoice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. <i>Nagoya Journal of Medical Science</i> , 2020 , 82, 151-160	0.7	1
3	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021 , 5, e617	0.3	1
2	Acetylation of PML Plays a Key Role in Histone Deacetylase Inhibitor-Mediated Apoptosis through Enhanced PML Sumoylation.. <i>Blood</i> , 2007 , 110, 4164-4164	2.2	
1	Retention but Significant Reduction of BCR-ABL Transcript in Hematopoietic Stem Cells in Chronic Myelogenous Leukemia after Imatinib Therapy.. <i>Blood</i> , 2008 , 112, 2116-2116	2.2	